1-6 of 6
Susan L. Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Ahrén, Susan L. Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Journal: Diabetes Care
Diabetes Care 2014;37(8):2141–2148
https://doi.org/10.2337/dc14-0024
Published: 12 July 2014
View article titled, HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Open the PDF for HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin in another window
Includes: Supplementary data
Journal Articles

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter
Journal: Diabetes Care
Diabetes Care 2014;37(8):2317–2325
https://doi.org/10.2337/dc14-0001
Published: 12 July 2014
View article titled, Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Open the PDF for Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro in another window
Includes: Supplementary data
Journal Articles

Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD)

Laura N. McEwen, PHD, Dori Bilik, MBA, Susan L. Johnson, MD, MS, Jeffrey B. Halter, MD, Andrew J. Karter, PHD, Carol M. Mangione, MD, Usha Subramanian, MD, Beth Waitzfelder, PHD, Jesse C. Crosson, PHD, William H. Herman, MD, MPH
Journal: Diabetes Care
Diabetes Care 2009;32(6):971–976
https://doi.org/10.2337/dc08-1911
Published: 19 February 2009
View article titled, Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: <subtitle>Translating Research into Action for Diabetes (TRIAD)</subtitle>
Open the PDF for Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: <subtitle>Translating Research into Action for Diabetes (TRIAD)</subtitle> in another window
Journal Articles

Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment? : The Translating Research Into Action for Diabetes (TRIAD) study

Susan L. Johnson, MD, MS, Edward F. Tierney, MPH, Kingsley U. Onyemere, MD, MPH, Chien-Wen Tseng, MD, MPH, Monica M. Safford, MD, Andrew J. Karter, PHD, Assiamira Ferrara, MD, PHD, O. Kenrick Duru, MD, Arleen F. Brown, MD, PHD, K.M. Venkat Narayan, MD, MSC, MBA, MRCP, Theodore J. Thompson, MS, William H. Herman, MD, MPH
Journal: Diabetes Care
Diabetes Care 2006;29(8):1733–1738
https://doi.org/10.2337/dc06-0260
Published: 01 August 2006
View article titled, Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment? : <subtitle>The Translating Research Into Action for Diabetes (TRIAD) study</subtitle>
Open the PDF for Who Is Tested for Diabetic Kidney Disease and Who Initiates Treatment? : <subtitle>The Translating Research Into Action for Diabetes (TRIAD) study</subtitle> in another window
Journal Articles

A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes

William H. Herman, MD, MPH, Liza L. Ilag, MD, MS, Susan L. Johnson, MD, Catherine L. Martin, MS, Joyce Sinding, MS, Abdulaziz Al Harthi, MD, Cynthia D. Plunkett, RNC, Frankie B. LaPorte, MS, Ray Burke, MA, Morton B. Brown, PHD, Jeffery B. Halter, MD, Philip Raskin, MD
Journal: Diabetes Care
Diabetes Care 2005;28(7):1568–1573
https://doi.org/10.2337/diacare.28.7.1568
Published: 01 July 2005
View article titled, A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes
Open the PDF for A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes in another window
Journal Articles

The Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population 45–74 Years of Age

Susan L. Johnson, MD, Bahman P. Tabaei, MPH, William H. Herman, MD, MPH
Journal: Diabetes Care
Diabetes Care 2005;28(2):307–311
https://doi.org/10.2337/diacare.28.2.307
Published: 01 February 2005
View article titled, The Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population 45–74 Years of Age
Open the PDF for The Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population 45–74 Years of Age in another window